{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:53:34Z","timestamp":1785549214080,"version":"3.56.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used as oral hypoglycemic agents in type 2 diabetes mellitus (T2DM) patients because of their cardiovascular and renal benefits. Euglycemic diabetic ketoacidosis (euDKA) is a serious and increasingly recognized complication of SGLT2i therapy. The atypical symptoms of euDKA may lead to delayed diagnosis and life-threatening outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>Here, we report a 48-year-old woman with T2DM and hypertension who was diagnosed with acute myocardial infarction (AMI). The patient underwent emergency percutaneous coronary intervention and received canagliflozin for heart failure. However, the patient presented with tachypnea, dyspnea, nausea, vomiting, and abdominal pain during the postoperative period. SGLT2i-associated euDKA was suspected to be the underlying cause of mild hyperglycemia, high anion gap metabolic acidosis, and ketonemia. The patient was successfully rescued by rapid correction of dehydration and electrolyte abnormalities and an insulin drip to normalize acidosis and bicarbonate levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusion:<\/jats:title>\n                    <jats:p>Although the early use of SGLT2i may improve cardiac function in patients with AMI and heart failure, our findings suggest that clinicians should be aware of the association between SGLT2i therapy and euDKA. SGLT2i should be avoided in acute cardiovascular crises until patient stabilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003750","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T17:00:09Z","timestamp":1755882009000},"page":"6802-6806","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["SGLT2i-induced euglycemic diabetic ketoacidosis in a heart failure patient with acute myocardial infarction: a case report"],"prefix":"10.1097","volume":"87","author":[{"given":"Jin","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"R1-20260204","doi-asserted-by":"crossref","first-page":"3720\u2013826","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"R2-20260204","doi-asserted-by":"crossref","first-page":"601\u201313","DOI":"10.1007\/s40256-022-00545-6","article-title":"SGLT2 inhibitors: new hope for the treatment of acute myocardial infarction?","volume":"22","author":"Wu","year":"2022","journal-title":"Am J Cardiovasc Drugs: Drugs, Dev, and Other Interv"},{"key":"R3-20260204","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R4-20260204","doi-asserted-by":"crossref","first-page":"1995\u20132008","DOI":"10.1056\/NEJMoa1911303","article-title":"Investigators, dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20260204","doi-asserted-by":"crossref","first-page":"819\u201329","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"R6-20260204","doi-asserted-by":"crossref","first-page":"297\u2013322","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R7-20260204","doi-asserted-by":"crossref","first-page":"673\u201382","DOI":"10.1080\/14740338.2020.1764532","article-title":"Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment","volume":"19","author":"Sampani","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R8-20260204","first-page":"401\u201311","article-title":"SGLT-2 inhibitors and euglycemic diabetic ketoacidosis\/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment","volume":"60","author":"He","year":"2023","journal-title":"Acta Diabetol"},{"key":"R9-20260204","doi-asserted-by":"crossref","first-page":"11\u201313","DOI":"10.1016\/j.ajem.2021.01.033","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2i use: case series","volume":"44","author":"Puls","year":"2021","journal-title":"Am J Emerg Med"},{"key":"R10-20260204","first-page":"2025","article-title":"Revised Surgical CAse REport (SCARE) guideline: an update for the age of artificial intelligence","volume":"2","author":"Ahmed","year":"2025","journal-title":"Prem J Sci"},{"key":"R11-20260204","doi-asserted-by":"crossref","first-page":"2117\u201328","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-20260204","first-page":"743\u201354","article-title":"Investigators, effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial, the lancet","volume":"9","author":"Heerspink","year":"2021","journal-title":"Diabetes & Endocrinol"},{"key":"R13-20260204","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata","year":"2021","journal-title":"Sci Rep"},{"key":"R14-20260204","doi-asserted-by":"crossref","first-page":"9\u201314","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski","year":"2019","journal-title":"Eur J Intern Med"},{"key":"R15-20260204","doi-asserted-by":"crossref","first-page":"102275","DOI":"10.1016\/j.dsx.2021.102275","article-title":"Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: a review of 72 cases over a 4.5-year period","volume":"15","author":"Menghoum","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"R16-20260204","doi-asserted-by":"crossref","first-page":"701\u201304","DOI":"10.1111\/imj.13442","article-title":"Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors","volume":"47","author":"Isaacs","year":"2017","journal-title":"Intern Med J"},{"key":"R17-20260204","doi-asserted-by":"crossref","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"key":"R18-20260204","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","article-title":"Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry","volume":"21","author":"Paolisso","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R19-20260204","doi-asserted-by":"crossref","first-page":"1931\u201344","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R20-20260204","first-page":"2058\u201368","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction","volume":"79","author":"Udell","year":"2022","journal-title":"JACC Rev Topic of the Week, J Am Coll Cardiol"},{"key":"R21-20260204","doi-asserted-by":"crossref","first-page":"883\u201391","DOI":"10.1111\/jcpt.13107","article-title":"The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk worth taking?","volume":"45","author":"Koufakis","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"R22-20260204","doi-asserted-by":"crossref","first-page":"ytad336","DOI":"10.1093\/ehjcr\/ytad336","article-title":"Unsuspected diabetic ketoacidosis after myocardial infarction in a patient treated with SGLT2 inhibitor increased length of stay in the hospital: how can it be prevented? A case report","volume":"7","author":"Oriot","year":"2023","journal-title":"Eur Heart J Case Rep"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:02:57Z","timestamp":1770217377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003750","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"2025-04-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}